{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:54:51Z","timestamp":1789469691588,"version":"build-2803163510"},"reference-count":0,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["int j tuberc lung dis"],"published-print":{"date-parts":[[2021,11,1]]},"abstract":"<jats:p><jats:bold>BACKGROUND:<\/jats:bold> Programmatic management of TB infection is a critical component of the WHO End TB Strategy. Interferon-gamma release assays (IGRAs) overcome some limitations of the tuberculin skin test, but implementation of IGRA testing in low-resource settings is challenging.<jats:bold>METHODS:<\/jats:bold>\n In this feasibility study, we evaluated performance of a novel digital lateral-flow assay, the QIAreach<jats:sup>\u00ae<\/jats:sup> QuantiFERON<jats:sup>\u00ae<\/jats:sup> TB (QIAreach-QFT) test, against the QuantiFERON<jats:sup>\u00ae<\/jats:sup>-TB Gold Plus (QFT-Plus) assay. A population with a mix of risk factors for TB\n infection (111 donors) were sampled over multiple days. A total of 207 individual blood samples were tested according to the manufacturer\u00b4s instructions.<jats:bold>RESULTS:<\/jats:bold> The overall percentage agreement was 95.6% (two-sided 95% CI 91.8\u201398), with a positive percentage agreement\n (i.e., sensitivity) of 100% (95% CI 94.7\u2013100) and a negative percentage agreement (i.e., specificity) of 95.6% (95% CI 90.6\u201398.4). All QFT-Plus positive specimens with TB1-Nil and TB2-Nil values less than 1 IU\/ml tested positive on QIAreach-QFT.<jats:bold>CONCLUSIONS:<\/jats:bold> QIAreach\n QFT is a deployable, accurate testing solution for decentralised testing. It has the potential to overcome key hurdles for TB infection screening in high-burden settings thus helping to achieve the WHO End TB programme goals.<\/jats:p>","DOI":"10.5588\/ijtld.21.0391","type":"journal-article","created":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T04:38:56Z","timestamp":1634963936000},"page":"917-922","source":"Crossref","is-referenced-by-count":19,"title":["Evaluation of a lateral-flow nanoparticle fluorescence assay for TB infection diagnosis"],"prefix":"10.5588","volume":"25","author":[{"given":"F.","family":"Stieber","sequence":"first","affiliation":[{"name":"Qiagen Inc, Germantown, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Howard","sequence":"additional","affiliation":[{"name":"Qiagen Inc, Germantown, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Manissero","sequence":"additional","affiliation":[{"name":"Qiagen Manchester Ltd, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Boyle","sequence":"additional","affiliation":[{"name":"Former Qiagen employee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Ndunda","sequence":"additional","affiliation":[{"name":"Former Qiagen employee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Love","sequence":"additional","affiliation":[{"name":"Former Qiagen employee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Yang","sequence":"additional","affiliation":[{"name":"Qiagen Inc, Germantown, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Schumacher","sequence":"additional","affiliation":[{"name":"Qiagen Inc, Germantown, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Uchiyama","sequence":"additional","affiliation":[{"name":"Qiagen Inc, Germantown, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Parsons","sequence":"additional","affiliation":[{"name":"Ellume Limited, East Brisbane, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Miller","sequence":"additional","affiliation":[{"name":"Ellume Limited, East Brisbane, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Douwes","sequence":"additional","affiliation":[{"name":"Ellume Limited, East Brisbane, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Mielens","sequence":"additional","affiliation":[{"name":"Ellume Limited, East Brisbane, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Laing","sequence":"additional","affiliation":[{"name":"Ellume Limited, East Brisbane, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Nikolayevskyy","sequence":"additional","affiliation":[{"name":"Qiagen Manchester Ltd, Manchester, UK, Imperial College, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3554","container-title":["The International Journal of Tuberculosis and Lung Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/iuatld\/ijtld\/2021\/00000025\/00000011\/art00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T04:39:14Z","timestamp":1634963954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.5588\/ijtld.21.0391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":0,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11,1]]}},"alternative-id":["1027-3719(20211101)25:11L.917;1-"],"URL":"https:\/\/doi.org\/10.5588\/ijtld.21.0391","relation":{},"ISSN":["1027-3719"],"issn-type":[{"value":"1027-3719","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,1]]}}}